References
- Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023.
- Anagnostou T, Riaz IB, Hashmi SK, et al. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Lancet Haematol. 2020;7:e816–e826.
- Myers RM, Li Y, Barz Leahy A, et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39:3044–3055.
- Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459.
- Baumeister SHC, Mohan GS, Elhaddad A, et al. Cytokine release syndrome and associated acute toxicities in pediatric patients undergoing immune effector cell therapy or hematopoietic cell transplantation. Front Oncol. 2022;12:841117.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–638.
- Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
- Cai C, Tang D, Han Y, et al. A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging (Albany NY). 2020;12:18741–18753.
- Zahid A, Siegler EL, Kenderian SS. CART cell toxicities: new insight into mechanisms and management. Clin Hematol Int. 2020;2:149–155.
- Grigor EJM, Fergusson D, Kekre N, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33:98–110.
- Brown BD, Tambaro FP, Kohorst M, et al. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis? Front Oncol. 2021;11:634445.
- Zhang B, Li X, Yin T, et al. Neurotoxicity of tumor immunotherapy: the emergence of clinical attention. J Oncol. 2022;2022:4259205.
- Lim FLWI, Yunxin C, Huang FJ, et al. A unique hub-and-spoke model to optimize patient management in lymphoma using novel chimeric antigen receptor-T cell therapy in Southeast and South Asia. Hematol Oncol. 2022;40:4–12.
- Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37(suppl 1):48–52.
- Baer B, Dudley CV, Simons RM. Management principles associated with cytokine release syndrome. Semin Oncol Nurs. 2019;35:150931.
- Silva LAGPD, Lopes VJ, Mercês NNAD. Symptom management theory applied to nursing care: scoping review. Rev Bras Enferm. 2021;74:e20201004.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
- Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404–1419.
- Rubin DB, Al Jarrah A, Li K, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77:1536–1542.
- Li Y, Ming Y, Fu R, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022;13:950923.
- Herr MM, Chen GL, Ross M, et al. Identification of neurotoxicity after chimeric antigen receptor (CAR) T cell infusion without deterioration in the immune effector cell encephalopathy (ICE) score. Biol Blood Marrow Transplant. 2020;26:e271–e274.
- Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell all patients. J Clin Invest. 2016;126:2123–2138.
- Granroth G, Rosenthal A, McCallen M, et al. Supportive care for patients with lymphoma undergoing CAR-T-cell therapy: the advanced practice provider’s perspective. Curr Oncol Rep. 2022;24:1863–1872.
- Alexander M, Culos K, Roddy J, et al. Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration. Transplant Cell Ther. 2021;27:558–570.
- Sokolov E, Karschnia P, Benjamin R, et al. Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. BMJ Neurol Open. 2020;2:e000054.
- Myers RM, Dolan J, Teachey DT. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. Expert Rev Clin Immunol. 2020;16:1029–1042.
- Gonzalez Castro LN, Dietrich J, Forst DA. Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES). J Cancer Res Clin Oncol. 2019;145:1917–1918.
- Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212–2221.
- Santomasso B, Bachier C, Westin J, et al. The other side of car T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433–444.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
- Luo W, Li C, Zhang Y, et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis. BMC Cancer. 2022;22:98.
- Smith M, Dai A, Ghilardi G, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28:713–723.
- Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.
- Knight JM, Szabo A, Arapi I, et al. Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Commun Med (Lond). 2022;2:49.
- Cusatis R, Balza J, Uttke Z, et al. Patient-reported cognitive function among hematopoietic stem cell transplant and cellular therapy patients: a scoping review. Qual Life Res. 2023;32:939–964.
- Serra López-Matencio JM, Gómez Garcia de Soria V, Gómez M, et al. Monitoring and safety of CAR-T therapy in clinical practice. Expert Opin Drug Saf. 2022;21:363–371.
- Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024–10028.
- Belin C, Devic P, Ayrignac X, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020;10:18997.